EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

TYRO3 , AXL , MERTK and Their Ligands in Brain Metastases From Colorectal Cancers

Anaïs Noblanc, Fatima Dkhissi, Pierre-Olivier Guichet, Lucie Lebeau, Serge Milin, Sheik Emambux, Pauline Roussille, Camille Evrard iD, Lucie Karayan-Tapon, David Tougeron, Omar Benzakour, Violaine Randrian iD

Cancer Medicine · 2026

DOI: 10.1002/cam4.71869 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2026. Verfasst von Anaïs Noblanc und 11 weiteren Autor:innen. Beteiligte Einrichtung: PRODICET, UR24144, Université de Poitiers, Poitiers, France. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Receptor Protein-Tyrosine Kinases, Proto-Oncogene Proteins, c-Mer Tyrosine Kinase. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sport et Collection 2020.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

TYRO3, AXL, and MERTK (TAM receptor tyrosine kinases) represent potential therapeutic targets in metastatic colorectal cancer. Pre‐clinical and clinical data are needed to explore further how TAM receptors interact with the central nervous system, which could impact brain metastases from colorectal cancer (BM‐CRC).

Methods

We analyzed TAM receptor expression in established brain metastasis stem cell lines from patients with CRC (BM‐SC‐CRC) (RNA and protein), a local cohort of BM‐CRC patients (protein), and a cohort of metastatic CRC from The Cancer Genome Atlas (TCGA) (RNA).

Results

When orthotopically injected into mice, BM‐SC‐CRC derived from two patients expressed TYRO3 and Protein S (PROS1) but poorly AXL and GAS6. When we analyzed both patients' primary tumors and metastatic sites, TYRO3 and AXL proteins were expressed in all tumor sites, but hardly MERTK. AXL was located primarily in endothelial cells, and TYRO3 in tumor cells. We examined the protein expression of TAM receptors in a cohort of BM‐CRC patients, considering tissue from the primary tumor ( N = 85), the matched brain metastases ( N = 40), and another metastatic site ( N = 29). AXL was expressed through primary tumors to brain metastases, as 72.7% of samples in BM (versus 44% with TYRO3 and 53% with MERTK) had a stable (45.5%) or increased (27.2%) protein expression compared to their paired primary tumor. None of the TAM receptors or PROS1 were found prognostic in a TCGA metastatic CRC cohort ( n = 80), but GAS6 was, in univariate (HR = 2.141 [95% CI 1.018–4.506], p = 0.045) and multivariate analysis (HR = 2.382 [95% CI 1.124–5.048], p = 0.024). In exploratory analysis, patients with Low AXL/High GAS6 had a poorer prognosis ( p = 0.046). Discussion and Conclusion The TAM receptors' ligand GAS6 and the AXL/GAS6 ratio could help to monitor patients' prognosis in metastatic CRC settings including BM‐CRC. Further research is needed to validate the TAM receptors' impact on prognosis in BM‐CRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsReceptor Protein-Tyrosine KinasesProto-Oncogene Proteinsc-Mer Tyrosine KinaseBrain NeoplasmsHumansAxl Receptor Tyrosine KinaseAnimalsGrowth Arrest-Specific Protein 6Intercellular Signaling Peptides and ProteinsMiceFemaleCell Line, TumorMaleLigandsProtein SAgedMiddle AgedPrognosis

Stichwörter der Autor:innen

AXLGAS6brain metastasiscolorectal cancer

Substanzen

Axl Receptor Tyrosine KinaseReceptor Protein-Tyrosine KinasesProto-Oncogene Proteinsc-Mer Tyrosine KinaseTYRO3 protein, humanGrowth Arrest-Specific Protein 6AXL protein, humanIntercellular Signaling Peptides and ProteinsMERTK protein, humanLigands

Autor:innen und Institutionen

  • PRODICET, UR24144, Université de Poitiers, Poitiers, France.
  • Department of Biological Cancerology, CHU de Poitiers, Poitiers, France.
  • Department of Pathology, CHU de Poitiers, Poitiers, France.
  • Department of Oncology, CHU de Poitiers, Poitiers, France.
  • Department of Radiotherapy, CHU de Poitiers, Poitiers, France.
  • Department of Hepatology and Gastroenterology, CHU de Poitiers, Poitiers, France.

ORCID-Profile: Camille Evrard, Violaine Randrian

Förderung

  • Sport et Collection 2020

Zitieren

APA

Noblanc, A., Dkhissi, F., Guichet, P. O., Lebeau, L., Milin, S., Emambux, S., Roussille, P., Evrard, C., Karayan-Tapon, L., Tougeron, D., Benzakour, O., & Randrian, V. (2026). TYRO3 , AXL , MERTK and Their Ligands in Brain Metastases From Colorectal Cancers. Cancer Medicine. https://doi.org/10.1002/cam4.71869

Vancouver

Noblanc A, Dkhissi F, Guichet PO, Lebeau L, Milin S, Emambux S, et al. TYRO3 , AXL , MERTK and Their Ligands in Brain Metastases From Colorectal Cancers. Cancer Medicine. 2026. doi:10.1002/cam4.71869

BibTeX
@article{Noblanc2026,
  author = {Noblanc, Anaïs and Dkhissi, Fatima and Guichet, Pierre-Olivier and Lebeau, Lucie and Milin, Serge and Emambux, Sheik and Roussille, Pauline and Evrard, Camille and Karayan-Tapon, Lucie and Tougeron, David and Benzakour, Omar and Randrian, Violaine},
  title = {TYRO3 , AXL , MERTK and Their Ligands in Brain Metastases From Colorectal Cancers},
  journal = {Cancer Medicine},
  year = {2026},
  doi = {10.1002/cam4.71869}
}
Kostenlos starten →